OGT, a Sysmex Group company, has launched the RNA-based SureSeq Myeloid Fusion Panel — a next-generation sequencing (NGS) tool for identifying key fusion genes implicated in acute myeloid leukaemia (AML).
Intelligently designed in collaboration with myeloid cancer experts, the panel can efficiently identify over 30 key disease-associated fusions in AML, including KMT2A and MECOM fusions, in a single assay. By utilising a partner-gene agnostic approach, fusions with multiple partners as well as novel and rare fusions can be identified, expanding the ability to classify samples.
The panel is fully compatible with OGT’s existing end-to-end Universal NGS Complete Workflow Solution and data analysis software, Interpret, to minimise hands-on time and provide easy analysis without the need for additional bioinformatics resources. It is a valuable tool for myeloid research that is supported by an efficient workflow, enabling users to rapidly detect the most relevant fusion genes in a single assay.
Phone: 02 9016 3040
Parse Biosciences Evercode BCR kits for mouse samples
The kits enable researchers to profile the mouse BCR repertoire alongside whole transcriptome...
OGT SureSeq CLL + CNV V3 Panel
The updated NGS panel offers users more comprehensive variant detection to improve confidence in...
Beckman Coulter Life Sciences Cydem VT Automated Clone Screening System
The system is designed to reduce time to market for biologic drug discovery and monoclonal...
